Chaudhary Khan, MD
Gastroenterology · O Fallon, MONPI 1649252461
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 400 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 33.3% of the total. Reporting peaked in 2024 at $1,561 and has fallen 76.1% since, to $373 in 2025.
Across 400 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$569
- Takeda Pharmaceuticals U.S.A., Inc.$461
- Sanofi$374
- Ironwood Pharmaceuticals, Inc$270
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,57799%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 146 | $2,560 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 67 | $1,100 |
| Johnson & Johnson | 30 | $569 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $461 |
| Sanofi | 8 | $374 |
| Ironwood Pharmaceuticals, Inc | 17 | $270 |
| Gilead | 11 | $251 |
| Regeneron Healthcare Solutions, Inc. | 6 | $235 |
| Romark Laboratories, LC | 12 | $230 |
| Pfizer | 13 | $207 |
| Ardelyx, Inc. | 11 | $183 |
| QOL Medical, LLC | 4 | $173 |
| Ipsen Biopharmaceuticals, Inc | 1 | $150 |
| Aimmune Therapeutics, Inc. | 7 | $145 |
| Merck | 9 | $129 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Nestle Healthcare Nutrition Inc. | 6 | $103 |
| Lilly USA, LLC | 4 | $80 |
| Redhill Biopharma Inc. | 4 | $68 |
| Albireo Pharma, Inc. | 1 | $64 |
| Bristol Myers Squibb | 4 | $62 |
| Biosense Webster, Inc. | 1 | $29 |
| Braintree Laboratories, Inc. | 2 | $28 |
| Olympus America Inc. | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,682 in reported general payments places this provider in the 75th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 25 | $60,678 |
| XifaxanRifaximin | 15 | $49,297 |
| LinzessLinaclotide | 46 | $43,010 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 115 | $7,050 |
| Lubiprostone | 17 | $4,399 |
| Pantoprazole Sodium | 303 | $3,623 |
| Dexlansoprazole DrDexlansoprazole | 14 | $3,425 |
| Ursodiol | 20 | $3,279 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 244 | $2,927 |
| Sucralfate | 19 | $2,550 |
| Famotidine | 97 | $1,781 |
| Omeprazole | 113 | $1,395 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 74 | $905 |
| Dicyclomine Hcl | 39 | $585 |
| Ondansetron Hcl | 357 | $540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,560 | $103,68871 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,100 | $49,29715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 374 gastroenterology providers in Missouri.
Other gastroenterology in O Fallon
- Gregory SayukSaint Louis$1.1M
- Katie SchroederSaint Louis$730K
- David AlpersSaint Louis$616K
- Kamran QureshiLake St Louis$279K
- Laith Al MomaniKansas City$249K
- Ahmed SaeedKansas City$246K
- Parakkal DeepakSaint Louis$205K
- Bradley AndersonColumbia$194K
- Mauricio Lisker MelmanSaint Louis$179K
- Matthew CiorbaSaint Louis$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.